S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.18 (+1.41%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.18 (+1.41%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.18 (+1.41%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
S&P 500   5,130.17 (+0.67%)
DOW   39,052.91 (+0.14%)
QQQ   445.18 (+1.41%)
AAPL   178.69 (-1.14%)
MSFT   414.93 (+0.31%)
META   501.98 (+2.42%)
GOOGL   138.16 (-0.22%)
AMZN   178.37 (+0.91%)
TSLA   204.33 (+1.21%)
NVDA   817.54 (+3.34%)
NIO   5.83 (+1.39%)
AMD   200.46 (+4.12%)
BABA   74.88 (+1.15%)
T   16.97 (+0.24%)
F   12.45 (+0.08%)
MU   95.68 (+5.60%)
CGC   3.26 (-0.91%)
GE   159.13 (+1.43%)
DIS   111.95 (+0.33%)
AMC   4.39 (+1.62%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.87 (+1.29%)
NASDAQ:BLTE

Belite Bio (BLTE) Stock Price, News & Analysis

$46.26
+0.01 (+0.02%)
(As of 12:51 PM ET)
Today's Range
$46.16
$46.54
50-Day Range
$39.10
$48.01
52-Week Range
$11.00
$48.60
Volume
6,764 shs
Average Volume
74,314 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.83

Belite Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3.1% Downside
$44.83 Price Target
Short Interest
Healthy
0.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Belite Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.33) to ($0.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

Medical Sector

823rd out of 957 stocks

Pharmaceutical Preparations Industry

379th out of 440 stocks


BLTE stock logo

About Belite Bio Stock (NASDAQ:BLTE)

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE Stock Price History

BLTE Stock News Headlines

Belite Bio Stock (NASDAQ:BLTE) Insider Trades
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Belite Bio to Participate in the BTIG Ophthalmology Day
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Belite Bio (NASDAQ: BLTE)
Expert Ratings for Belite Bio
See More Headlines
Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/01/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BLTE
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.83
High Stock Price Target
$60.00
Low Stock Price Target
$25.00
Potential Upside/Downside
-3.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
23,931,000
Market Cap
$1.28 billion
Optionable
Not Optionable
Beta
-1.56
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














BLTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings
or view top-rated stocks.

What is Belite Bio's stock price target for 2024?

7 Wall Street research analysts have issued 12 month target prices for Belite Bio's stock. Their BLTE share price targets range from $25.00 to $60.00. On average, they anticipate the company's stock price to reach $44.83 in the next twelve months. This suggests that the stock has a possible downside of 3.1%.
View analysts price targets for BLTE
or view top-rated stocks among Wall Street analysts.

How have BLTE shares performed in 2024?

Belite Bio's stock was trading at $45.75 on January 1st, 2024. Since then, BLTE stock has increased by 1.1% and is now trading at $46.26.
View the best growth stocks for 2024 here
.

Are investors shorting Belite Bio?

Belite Bio saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 47,200 shares, a decline of 11.3% from the January 31st total of 53,200 shares. Based on an average daily volume of 96,000 shares, the days-to-cover ratio is currently 0.5 days.
View Belite Bio's Short Interest
.

When is Belite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BLTE earnings forecast
.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc (NASDAQ:BLTE) posted its earnings results on Monday, November, 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09.

When did Belite Bio IPO?

(BLTE) raised $36 million in an IPO on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

Who are Belite Bio's major shareholders?

Belite Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (0.13%), Cubist Systematic Strategies LLC (0.06%), Point72 Asset Management L.P. (0.03%), Jump Financial LLC (0.02%) and Virtus ETF Advisers LLC (0.01%).

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLTE) was last updated on 3/1/2024 by MarketBeat.com Staff